Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial LtdfiledCriticalMerial Ltd
Priority to MYPI20060392priorityCriticalpatent/MY141874A/en
Publication of MY141874ApublicationCriticalpatent/MY141874A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Medicinal Preparation
(AREA)
Abstract
THE PRESENT INVENTION PROVIDES FOR A NOVEL OIL-IN-WATER (O/W) EMULSION, WITH INCREASED STABILITY IN THE PRESENCE OF BACTERIAL OR VIRAL SUSPENSIONS, ESPECIALLY THOSE CONCENTRATED AND NON-PURIFIED OR WEAKLY PURIFIED. THE EMULSION OF THE PRESENT INVENTION CAN ACT AS VEHICLE FOR THE DELIVERY OF A PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE IMMUNOGEN AND, IN PARTICULAR, AN IMMUNOGEN SELECTED FORM THE GROUP COMPRISING AN INACTIVATED PATHOGEN, AN ATTENUATED PATHOGEN, A SUBUNIT, A RECOMBINANT EXPRESSION VECTOR, AND A PLASMID OR COMBINATIONS THEREOF. IN ONE EMBODIMENT, THE PRESENT INVENTION PROVIDES FOR AN INJECTABLE OIL-IN-WATER (O/W) EMULSION COMPRISING: (1) AN AQUEOUS SOLUTION CONTAINING AN IMMUNOGEN, SAID IMMUNOGEN SELECTED FROM THE GROUP COMPRISING AN INACTIVATED MYCOPLASMA HYOPNEUMONIAE BACTERIUM, AN INACTIVATED D PORCINE CIRCOVIRUS TYPE 2 (PCV-2) VIRUS OR COMBINATIONS THEREOF; (2) A MINERAL OIL; (3) A NON-IONIC LIPOPHILIC SURFACTANT; AND (4) A NON-IONIC HYDROPHILIC SURFACTANT HAVING A LOW HLB VALUE WHICH COMPRISES ETHOXYLATED FATTY ACID DIESTERS OF SORBITAN (GENERALLY HAVING HLB VALUE BETWEEN 11 AND 13).
MYPI200603922006-01-272006-01-27Vaccine formulations comprising an oil-in-water emulsion
MY141874A
(en)
Use of flaviviruses for the expression of protein epitopes and for the development of a novel live attenuated vaccine virus for immunization against flaviviruses and other infectious agents.
IMMUNOGENIC COMPOSITION THAT INCLUDES AT LEAST ONE ANTIGEN OF THE VIRUS OF THE INACTIVATED DENGUE AND AN ADJUVANT WITHOUT ALUMINUM, METHOD FOR PRODUCING THIS VACCINE AND ITS USE TO PREPARE A MEDICINAL PRODUCT
BINDING DOMAIN, ISOLATED NUCLEIC ACID, CASSETTE AND EXPRESSION VECTOR, RECOMBINANT VIRUSES AND ITS USE, PHARMACEUTICAL COMPOSITION, AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 AND/OR PREVENTION OF SARS-RELATED CORONAVIRUS INFECTION COV-2
Polyprotein, nucleic acid molecule, plasmid, recombinant vaccine or attenuated vaccine, pharmaceutical composition, and method for immunizing an individual against HIV.